BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 23387553)

  • 1. Is pelvic lymph node dissection required at radical prostatectomy for low-risk prostate cancer?
    Mitsuzuka K; Koie T; Narita S; Kaiho Y; Yoneyama T; Kawamura S; Tochigi T; Ohyama C; Habuchi T; Arai Y
    Int J Urol; 2013 Nov; 20(11):1092-6. PubMed ID: 23387553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
    Berglund RK; Sadetsky N; DuChane J; Carroll PR; Klein EA
    J Urol; 2007 Feb; 177(2):526-29; discussion 529-30. PubMed ID: 17222625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
    Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
    BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Aug; 12(8):739-44. PubMed ID: 16174048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
    Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA
    Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of pelvic lymphadenectomy in the therapy of prostate and bladder cancer].
    Heidenreich A; Ohlmann CH
    Aktuelle Urol; 2005 Jun; 36(3):219-29. PubMed ID: 16001337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Novara G; Wilson TG
    BJU Int; 2013 Jul; 112(1):81-8. PubMed ID: 23351148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.
    Hansen J; Rink M; Bianchi M; Kluth LA; Tian Z; Ahyai SA; Shariat SF; Briganti A; Steuber T; Fisch M; Graefen M; Karakiewicz PI; Chun FK
    Prostate; 2013 Jan; 73(2):211-8. PubMed ID: 22821742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
    Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Comprehensive Cancer Network practice guidelines 2011: Need for more accurate recommendations for pelvic lymph node dissection in prostate cancer.
    Abdollah F; Sun M; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Passoni N; Karakiewicz PI; Rigatti P; Montorsi F; Briganti A;
    J Urol; 2012 Aug; 188(2):423-8. PubMed ID: 22698627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection.
    Walz J; Bladou F; Rousseau B; Laroche J; Salem N; Gravis G; Briganti A; Chun FK; Karakiewicz PI; Fournier G
    Urology; 2012 Mar; 79(3):546-51. PubMed ID: 22386393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores.
    Briganti A; Larcher A; Abdollah F; Capitanio U; Gallina A; Suardi N; Bianchi M; Sun M; Freschi M; Salonia A; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):480-7. PubMed ID: 22078338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.
    Touijer K; Rabbani F; Otero JR; Secin FP; Eastham JA; Scardino PT; Guillonneau B
    J Urol; 2007 Jul; 178(1):120-4. PubMed ID: 17499306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvic lymph node dissection for prostate cancer: frequency and distribution of nodal metastases in a contemporary radical prostatectomy series.
    Godoy G; von Bodman C; Chade DC; Dillioglugil O; Eastham JA; Fine SW; Scardino PT; Laudone VP
    J Urol; 2012 Jun; 187(6):2082-6. PubMed ID: 22498221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of pelvic lymph node dissection in prostate cancer: the New York PLND nomogram.
    Kazzazi A; Djavan B
    Can J Urol; 2011 Apr; 18(2):5585-91. PubMed ID: 21504645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the risk of lymph node invasion during radical prostatectomy using the European Association of Urology guideline nomogram: a validation study.
    Schmitges J; Karakiewicz PI; Sun M; Abdollah F; Budäus L; Isbarn H; Bianchi M; Trinh QD; Schlomm T; Chun FK; Graefen M; Steuber T
    Eur J Surg Oncol; 2012 Jul; 38(7):624-9. PubMed ID: 22531769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.